Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer (vol 15, pg 122, 2010)

被引：11
|
作者：
Schwartzberg, Lee S.
Franco, Sandra X.
Florance, Allison
O'Rourke, Lisa
Maltzman, Julie
Johnston, Stephen
机构：
来源：
ONCOLOGIST | 2010年 / 15卷 / 03期
关键词：
D O I：
10.1634/theoncologist.2009-0240erratum
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [31] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
    Fabi, Alessandra
    Russillo, Michelangelo
    Ferretti, Gianluigi
    Metro, Giulio
    Nistico, Cecilia
    Papaldo, Paola
    De Vita, Ferdinando
    D'Auria, Giuliana
    Vidiri, Antonello
    Giannarelli, Diana
    Cognetti, Francesco
    BMC CANCER, 2012, 12
  • [32] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, C. S.
    Paluch-Shimon, S.
    Campone, M.
    Petrakova, K.
    Blackwell, K. L.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D. A.
    Mondal, S.
    Su, F.
    Miller, M.
    Elmeliegy, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2018, 29 (07) : 1541 - 1547
  • [33] First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER
    Tripathy, Debu
    Kaufman, Peter A.
    Brufsky, Adam M.
    Mayer, Musa
    Yood, Marianne Ulcickas
    Yoo, Bongin
    Quah, Cheng
    Yardley, Denise
    Rugo, Hope S.
    ONCOLOGIST, 2013, 18 (05): : 501 - 510
  • [34] Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
    Doss, Sally
    Robertson, Janet
    Adam, Jane
    LANCET ONCOLOGY, 2012, 13 (08): : 766 - 767
  • [35] Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
    Yuan, Yang
    Zhang, Shaohua
    Wang, Tao
    Bian, Li
    Yan, Min
    Yin, Yongmei
    Song, Yuhua
    Wen, Yi
    Li, Jianbin
    Jiang, Zefei
    CHINESE MEDICAL JOURNAL, 2023, 136 (12) : 1459 - 1467
  • [36] Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
    Yuan Yang
    Zhang Shaohua
    Wang Tao
    Bian Li
    Yan Min
    Yin Yongmei
    Song Yuhua
    Wen Yi
    Li Jianbin
    Jiang Zefei
    中华医学杂志英文版, 2023, 136 (12)
  • [37] Hormone therapy versus chemotherapy as first-line treatment for estrogen receptor-positive metastatic breast cancer (MBC) patients
    Chang, T. Y.
    Lin, C.
    Lu, Y.
    Kuo, S. H.
    Huang, S.
    Huang, C.
    Cheng, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.
    Yuan, Zhongyu
    Huang, Jia-Jia
    Hua, Xin
    Zhao, Jian-Li
    Lin, Ying
    Zhang, Yuan-Qi
    Wu, Zhiyong
    Zhang, Lehong
    Bi, Xiwen
    Xia, Wen
    Zhong, Yong-Yi
    Wang, Shu-Sen
    Xu, Fei
    Hong, Ruoxi
    Jiang, Kuikui
    Shi, Yanxia
    Xue, Cong
    An, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer Reply
    Ellis, Matthew J.
    Robertson, John F. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (16) : 1960 - +
  • [40] Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast CancerProfile Report
    Monique P. Curran
    BioDrugs, 2011, 25 : 53 - 54
12345